The role of chloroquine phosphate on acute phase reactant proteins in patient with knee osteoarthritis Iraqi J Pharm Sci , Vol.18 (1) ,2009 Chloroquine and knee osteoarthritis 56 The Role of Chloroquine Phosphate on Acute Phase Reactant Proteins in Patients with Knee Osteoarthritis # Eman S. Saleh *, 1 , Kismet M.Turki ** and Mohammed H.Al-Osami *** *Department of Clinical Laboratory Sciences,College of Pharmacy,University of Baghdad,Baghdad , Iraq. ** College of Medicine , University of Baghdad , Baghdad , Iraq . ***Department of Rheumatology and Rehabilitation . Medical Baghdad City ,Baghdad , Iraq . Abstract The acute phase response is a major pathophysiologic phenomenon that accompanies inflammation whether acute or chronic. Complement (C3 and C4) and C - reactive protein (CRP) are positive acute phase proteins (+ ve APPs ). Their production takes place in hepatocyte and the blood concentration of these parameters are increased in osteoarthritis (OA). Chloroquine (CQ) is a diprotic weak base traditionally used to treat malaria. Recently the phosphate salt of CQ is used to decrease this type of (+ve APPs) . In this study, patients who suffered from knee osteoarthritis (KOA) are treated with oral dosage form of chloroquine phosphate (CQP) for one month, twice daily. Our results demonstrate that CQP improves the patient status by decreasing complement and C-reactive protein in blood. Key words: Chloroquine , knee osteoarthritis , acute phase proteins , complement , C-reactive protein. الخالصة نذٖ انًشضٗ انزيٍ يعإٌَ CRP, C4, C3نقذ ذًد دساعح دٔس عقاس فٕعفاخ انكهٕساكٕيٍ عهٗ يغرٕٖ انثشٔذيُاخ انرفاعهيح 22اَثٗ ٔ 45يشيضا ) 44ركش( ٔ 25أَثٗ , 35شخصا يٍ االصحاء ) 55يٍ انفصال انعظًي نهشكثح.أجشيد ذجشتح عشٕائيح عهٗ ( ذى ذشخيصٓى يٍ قثم انطثية 2552ُح انطة انعيادج االعرشاسيح يٍ) شٓش كإٌَ انثاَٗ انٗ ايهٕل ركش( في يغرشفٗ يذي االخرصاصي حغة طشيقح انكهيّ األيشيكيّ نًثحث انشثيّ حيث ذى ذحشيض األعشاض تٕاعطح يؤشش ) كهيكشيٍ ٔنٕسَظ ( نهفصال ٔ C3يع يغرٕٖ كم يٍ أنًرًًيٍ C -د يغرٕٖ انثشٔذيٍ انرفاعهيانعظًي ، أخزخ صٕس شعاعيّ أياييّ خهفيّ نًفصم انشكثّ ٔحذ C4( يشذيٍ تانيٕو ٔنًذج شٓش. عحثد عيُح يٍ دو االصحاء ٔانًشضٗ 255. ٔصف نٓى حثٕب فٕعفاخ انكهٕساكٕيٍ ترشكيض )يهغى نرفاعهيح في انًصم. نٕحظ اَخفاض أالً ثى عيُح يٍ دو انًشضٗ انزيٍ اعرعًهٕا ْزا انعقاس تعذ شٓش نغشض قياط َغة انثشٔذيُاخ ا يغرٕياخ ْزِ انعٕايم تصٕسج ٔاضحح ٔيعُٕيح عُذ اعرعًال انعالج حيث صيادذٓا ذهعة دٔسا يًٓا في ذغشيع ذآكم انغضاسيف ٔذكٕيٍ .يحانُرٕءاخ انعظً Introduction: OA is the most common disease in the world and a major cause of pain and disability which usually develops in distal inter phalangeal ( DIP )joints of finger, the weight bearing joints of leg and the movable portion of spine (1) . It is associated with a breakdown of cartilage in any joint in the body (2) . Pathologically, OA was defined as a gradual loss of articular cartilage combined with thickening of subchondral bone/ bony out growth (osteophyte) at joint margins with mild to chronic non specific synovial inflammation (3) . CQ is 4 -aminoquinoline approved for treatment and prophylaxis of malaria. Recently CQP is used by some authors in the OA as disease modifying anti –rheumatic drug ( DMARD) (4) , claimed to cause lowering of blood level of proinflammatory mediators (5) . Our study shows the effect of CQP on the serum concentration of CRP, C3 and C4 in patients with KOA.C-reactive protein is a laboratory marker that is important in the assessment of inflammation, serve as a predictor and indicator of response to therapy and overall outcome in various disorders (6) . The major function of CRP is to bind phosphocholine, this is by permitting recognition of foreign pathogens and phospholipid constituents of damaged cells (7) , so the activation of complement system and / or binding to phagocytic cells will take place , and to initiate elimination of targeted cells by interaction with both humoral and cellular affecter system of inflammation , as aresult CRP is a component of innate immune response (8) ,and useful in early detection of low grade inflammation (9) . # Based on oral presentation in the seventh scientific conference of the College of Pharmacy /University of Baghdad held in 26-27 November 2008 . 1 Corresponding author E-mail : www.Faith_1960@yahoo.com Received : 31/12/2008 Accepted : 28/3/2009 http://www.Faith_1960@yahoo.com/ Iraqi J Pharm Sci , Vol.18 (1) ,2009 Chloroquine and knee osteoarthritis 57 C3 and C4 serve proinflammatory roles, including chemotaxis, plasma protein exudation at the site of inflammation and opsonization of infectious agents and damaged cells (10) .C3 is beta - 2 protein 180 KDa , cleave by C3 convertase into C3a and C3b. C3b reacts with factor B to produce more C3 convertase and activate C5, so the serum level of C3 is increased in acute inflammation (11) . C4 is beta -1 protein, 210 KDa cleave by C1s to produce C4a and C4b, C4b interact with C2b to activate classical pathway C3 convertase. (12) Patients and method Fifty healthy people (30 female and 20 male) as control and seventy - four patients (45 female and 29 male) are selected randomly from the Out Patient Clinic in Baghdad Teaching Hospital / Medical City / Baghdad from January to September 2008 with inflammatory KOA diagnosed according to American College of Rheumatology (13) . All patients were assessed by Kellegren and Lawrence grading criteria for radiographic severity of knee osteoarthritis with different signs and symptoms such as joint pain, stiffness, bony enlargement, bony tenderness and crepitus (14) . Their ages are ranged from ( 45 to 78 ) years with mean value ± standard error of mean ( 55.07 ± 6.18).Chloroquine phosphate tablet (Medoquine 250mg/ Medochem Company is equivalent to 150mg CQ base), was prescribed by Rheumatologist as twice daily after meal for one month,because CQP is 4-aminoquinoline derivative( CQ+phosphate) ,it absorbed completely and rapidely from GIT ,its mean absorption half –life is four hours with a lag time slightly more than 30 minutes (15,16) ,and its duration of action is extended from sixteen to forty five days (17) .The serum analysis of all patients and control was done in the General Health Laboratory Center / Baghdad, before using this drug and one month later in order to estimate the level of C3, C4 and CRP.C3 and C4 are determined by Radial Immune Diffusion (11) while CRP is assessed turbidit- metrically by antigen antibody reaction technique (17) . Results were analysed by statistical package for social science (SPSS). Results The presented data in this study showed the comparisons between level of C3,C4 in microgram per milliliters (μg/ml) and CRP in milligram per liter(mg/ l) in healthy and patients before the treatment as well as after one month of using chloroquine phosphate are depicted in table (1),figures(1,2,3).There were a significant decrease in C3,C4 and CRP in male,female and total patients compared to their level at baseline and control. Table (1): The serum level of C3,C4 and CRP before using CQP at baseline and after one month of the treatment. Control Baseline P value Control, Baseline After one month P value Pre-,post- treatment C3 (μg/ml) T M F 950.1±21.1 877.3±17.3 987.4±20.2 1794.4±34.2 1788.2±48.8 1798.4±47.16 S p>0.01 1504.5±31.1 1503.4±40.9 1505.3±41.7 S P<0.05 C4 (μg/ml) T M F 320.23±12.2 318.1±15.7 307.2±13.4 396.08±14.6 367.7±20.2 414.3±19.9 S p>0.01 325.03±12.7 288.03±17.1 323.09±17.9 S P<0.05 CRP (MG/l) T M F 1.08±0.1 1.1±0.12 2.09±0.17 4.3±0.3 3.8±0.6 4.63±0.4 S p>0.01 2.02±0.2 1.8±0.37 2.1±0.23 S P<0.05 SEM: Standard error of mean. Significant P value : (P<0.05),(P>0.01). Iraqi J Pharm Sci , Vol.18 (1) ,2009 Chloroquine and knee osteoarthritis 58 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Total Male Female control pre-treatment post-treatment Figure (1): The level of serum C-reactive protein at baseline (pre-treatment), after one month of using chloroquine phosphate (post-treatment) and control. 0 200 400 600 800 1000 1200 1400 1600 1800 2000 Total Male Female control pre-treatment post-treatment Figure (2): The level of serum complement three at baseline and one month later of using chloroquine phosphate. 0 50 100 150 200 250 300 350 400 450 Total Male Female control pre-treatment post-treatment Figure (3): The level of serum complement four at baseline and one month later of using chloroquine phosphate. Iraqi J Pharm Sci , Vol.18 (1) ,2009 Chloroquine and knee osteoarthritis 59 Discussion C3, C4 and CRP are components of +ve APPs , their production are increased by hepatocyte (18) . The elevation of these proteins are detected in patient with OA which is due to releasing of inflammatory molecules (cytokines) (19) . Jawad et al in 2004 (4) demonstrated that the using of CQP as DMARD for three months in patients with KOA, lead to decrease the serum CRP level. In our study the presented data shows a significant decrease in this parameter after one month of using CQP (p<0.05), table (1), figure (1), so our result is in agreement with all explanation and findings. Chloroquine phosphate decreases serum level of CRP, C3 and C4 depending on it's ability to enter lysosomes and all acidic compartments of the cells (lysosomotropic effect) (20) . It interferes with intracellular processing, receptor recycling (21) and the secretion of proteins which lead to decrease the production of cytokines and other inflammatory mediators decreases lymphocyte proliferation as an immune effect (22) . Non - lysosomotropic effect of CQP includes the inhibition of phospholipase, antagonization of prostaglandin stabilization of lysosomal membrane in synoviocytes (23,24,25) . In 2006 , Numman et al used silymarin to treat patients with KOA instead of CQP (26) . Silymarin is a plant (mixture of flavolignans),isolated from the ripe seeds of Silybum marianum (Milk Thistle), it proved to have effective inhibitory effects on cyclooxygenase and 5- lipooxygenase in vitro and experimental animals (27) . Their results showed that this drug when prescribed for two months in KOA, it decreases the serum level of C3 and C4 significantly. Our study shows a significant decrease in C3 and C4 at the end of trial ( p<0.05) table (1), figure (2) and (3). All findings, trials in addition to the mode of action of CQP are supported the results. Conclusion: CRP, C3 and C4 are decreased after using CQP for one month in patients with KOA. Recommendation Further study is needed to asses other parameters in serum and synovial fluid. References 1. Morehead K , Sack KE . Osteoarthritis : What therapies for this disease of many causes ? Postgraduate Med . 2003;114, 5. 2. Brandt KD .Osteoarthritis. In: Kasper DL(ed) .Harrison , s Principles of-Internal- Medicine,6 th . ed ,McGraw-Hill Companies,2005;2036-45. 3. Berenbaum F. Osteoarthritis: A. Epidemiology, Pathology and Pathogenesis . In: Klippl JH, Crofford LJ, Stone JH, Wegand CM (eds). Primer on rheumatic disease 12 th ed. Atlanta, Georgia. Arthritis Foundation, 2001; P.285-89. 4. Jawad HM, Salman S ,Mohammed L. The effect of chloroquine phosphate as a disease modifying agent in osteoarthritis . Ph D thesis submitted to University of Baghdad/College of Medicine and the committee of postgraduate studies in Clinical Pharmacology, 2004. 5. Jelab A, Jawad HM, Salman S, Mohammed L: The effect of chloroquine phosphate on pro-inflammatory interleukins in osteoarthritis. MSc thesis submitted to University of Baghdad/College of Medicine and the committee of postgraduate studies in Clinical Pharmacology,2007. 6. Baddour VT , Bradley JD . Clinical assessment and significance of inflammation in knee osteoarthritis. Curr Rheumatol Rep,1999;1:59-63. 7. Volanakis JE. Acute phase protein in rheumatic disease. In: Koopman WJ (ed.).Arthritis and allied condition. A Textbook of Rheumatology. Williams Wilkins, Baltimore 1997; P.505. 8. Hoffman JA, Kafatos FC, Janeway CA, Ezekowitz RA.Phylogenetic perspective in innate immunity.Science,1999;248,1313. 9. Visser M, Bouter LM,McQuillan GM,et al. Elevated C- reactive protein levels in over weight and obese adult .JAMA,1999;282, 2131-35. 10. Molenaar ET,Voskuyl AE,et al. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum, 2001;44, 997. 11. Feldkamp CS. Immunochemical techniques. In: Kaplan LA, Pesce AJ, Kazmierczak SC (eds.) , Fourth Edition. Textbook of Clinical Chemistry , Mosby USA,2003, P.227-45. 12. Kyle RA. Classification and diagnosis of monoclonal gamma pathies. In: Rose NR, Friedman H and Fahey JL (eds.). Manual of clinical laboratory immunology (3 rd ed.). Washington DC; American Society of Microbiology 1986; P.152. 13. Recommandation for the medical management of osteoarthritis of the hip and knee.Update. American College of Iraqi J Pharm Sci , Vol.18 (1) ,2009 Chloroquine and knee osteoarthritis 60 Rheumatology, Subcommittee on Osteoarthritis Guidelines .Arthritis Rheum,2000;43,P.1905. 14. Kellgren HJ, Lawrence JS. Radiologic assessment of osteoarthritis. Ann Rheum Dis,1957;16, 494-501. 15. Smith DG, Aronson JK. Drug for arthritis. In: Grahame-Smith DG(ed.), Textbook of clinical pharmacology and drug therapy ,3 rd . ed ,Oxford University Press.2002;P.355-56, 509-10. 16. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus,1996; 5, 11. 17. Black S, Kushner I, Samols D. Serum C- reactive protein. J Biol. Chem.,2004; 279, 478. 18. Morley JJ, Kushner I. Serum C-reactive protein level in diseases. Ann NY Acad. Sci. ,1982; 389, 406. 19. Gabay C, Kushner I. Acute phase protein and other systemic responses to inflammation. N Engl. J Med.,1999; 340, 448. 20. Petri M. Hydroxychloroquine use in Baltimore Lupus Cohort: Effect on lipid ,glucose and thrombosis.Lupus,1996; 5, 16. 21. Rynes RI: Anti- malarial drug . In: Kelley WN , Harris ED JR, Ruddy S, Sledge CB (eds.) .Textbook of Rheumatology, (5 th ed.) . WB Saunders. Philadelphia ,1997; P.59-1. 22. Karres I, Kremer JP, Dietle I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokines release into human whole blood. Am J Physiol/ Regul Integ Comp Physiol, 1998; 274, 1058-64. 23. Fox R. Anti- malarial drug. Possible mechanism of action in autoimmune disease and prospects for drug development. Lupus, 1996; 5, 4. 24. Wallace DJ. Anti-malarial therapies In: Wallace DJ, Hahu BH (eds.). Dubois lupus erythematosus ( 5 th ed.) Williams Wilkins, Baltimore, 1997;P. 1117. 25. Stuhimeier KM. Mepacrine inhibits matrix metallo proteinase-1 (MMP-1) and (MMP-9) activation in human fibroblast- like synoviocyte. J Rheumatol, 2003; 30, 2330. 26. Numan IT, Hussain SA, Al-Ani TA. Evaluation of the clinical use of silymarin in knee osteoarthritis: Application of dual inhibition concept of cycloxygenase and 5-lipoxygnase, a Ph D thesis submitted to University of Baghdad/College of Pharmacy and the committee of postgraduate studies in Pharmacology, 2006. 27. Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm,1999;56,1195-97.